Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2613-2620

  Sridhara, Rajeshwari ^a   Mandrekar, Sumithra J ^c   Dodd, Lori E ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LAPATINIB;

ARTICLE; BREAST CANCER; DATA BASE; DISEASE COURSE; HER2 POSITIVE METASTATIC BREAST CANCER; HUMAN; IMAGE ANALYSIS; INDEPENDENT RADIOLOGIC COMMITTEE; INTERVAL CENSORING; KIDNEY METASTASIS; LEFT CENSORING; LUNG NON SMALL CELL CANCER; MEASUREMENT ERROR; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROGRESSION FREE SURVIVAL; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGHT CENSORING; STATISTICAL ANALYSIS; TREATMENT WITHDRAWAL; TUMOR GROWTH; TUMOR VOLUME; BIOASSAY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METHODOLOGY; NEOPLASMS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; STANDARDS; STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84878070728     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2938     Document Type: Article

References (24)

1. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 2010;102:230-43.
2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
3. Sullivan DC, Schwartz LH, Zhao B. The imaging viewpoint: how imaging affects determination of progression-free survival. Clin Cancer Res 2013;19:2621-8.
4. Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008;26:3791-6.
5. Korn EL, Dodd LE, Freidlin B. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials. Clin Trials 2010;7:626-33.
6. Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics 2011;67: 1092-9.
7. Sun J. The statistical analysis of interval-censored failure time data, New York: Springer 2006.
8. Wellner JA, Zhan Y. A hybrid algorithm for computation of the nonparametric maximum likelihood estimator from censored data. J Am Stat Assoc 1997;92:945-59.
9. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, et al. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer 2012;118:5358-65.
10. Stone Am, Bushnell W, Denne J, Sargent DJ, Amit O, et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 2011;47:1763-71.
11. Sun J, Zhao Q, Zhao X. Generalized log-rank tests for interval-censored failure time data. Scandinavian J Stat 2005;32:49-57.
12. National Research Council. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010.
13. Lapatinib product label, Section 14.1. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022059s013lbl.pdf
14. Borradaile K, Ford R, O'Neal M, Byme K. Discordance between BICR readers. Applied Clin Trials 2010. Available from: http://www. appliedclinicaltrialsonline.com/appliedclinicaltrials/Labs/Discordance-Between- BICR-Readers/ArticleStandard/Article/detail/693554
15. Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011;47: 1772-8.
16. Zhang JJ, Chen H, He K, Tang S, Justice R, Keegan P, et al. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: a meta-analysis. Drug Inf J 2013;47:167-74.
17. Oncologic Drug Advisory Committee. July 24, 2012 Meeting. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/ OncologicDrugsAdvisoryCommittee/ucm285400. htm
18. Zhang JJ, Zhang L, Chen H, Murgo AJ, Dodd LE, Pazdur R, et al. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials. Clin Cancer Res 2013;19:2637-45.
19. FDA Guidance for Industry: clinical trial endpoints for the approval of cancer drugs and biologics; 2007. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf
20. Hong S, Schmitt N, Stone A, Denne J. Attenuation of treatment effect due to measurement variability in assessment of progression-free survival. Pharm Statistics; 11:394-402.
21. International Conference on Harmonisation (ICH) Topic E9. 1998.
22. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-42.
23. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol 2009:27:5958-64.
24. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, et al. Lessons learned from independent central review. Eur J Cancer 2009;45:268-74.